EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Iptacopan in IgA Nephropathy — Final 24-Month Data

Jonathan Barratt, Necmi Eren, Naoki Kashihara, Bart Maes, Dana V Rizk, Brad Rovin, Hernán Trimarchi, Hong Zhang, Weiming Wang, Ismail Kocyigit, Chuanming Hao, Vladimir Tesař und 18 weitere

New England Journal of Medicine · 30.07.2026 · 395 (5) · 465-477

DOI: 10.1056/nejmoa2600743 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 30.07.2026. Verfasst von Jonathan Barratt und 29 weiteren Autor:innen. Beteiligte Einrichtung: Mayer IgA Nephropathy Laboratories, University of Leicester, Leicester, United Kingdom. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Proteinuria, Complement Inactivating Agents, Complement Factor B. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAProteinuriaComplement Inactivating AgentsComplement Factor BRenal InsufficiencyAdultFemaleHumansMaleMiddle AgedCreatinineDisease ProgressionDouble-Blind MethodGlomerular Filtration RateKaplan-Meier EstimateBenzoatesIndolesPiperidinesRenal DialysisKidney TransplantationTreatment Outcome

Substanzen

CreatinineiptacopanComplement Inactivating AgentsBenzoatesIndolesPiperidinesComplement Factor B

Autor:innen und Institutionen

  • Mayer IgA Nephropathy Laboratories, University of Leicester, Leicester, United Kingdom.
  • John Walls Renal Unit, Leicester General Hospital, Leicester, United Kingdom.
  • Kocaeli University, Kocaeli, Turkey.
  • Kawasaki Medical School, Okayama, Japan.
  • AZ Delta, Roeselare, Belgium.
  • University of Alabama at Birmingham, Birmingham.

ORCID-Profile: Julia Weinmann-Menke

Förderung

  • Novartis

Zitieren

APA

Barratt, J., Eren, N., Kashihara, N., Maes, B., Rizk, D. V., Rovin, B., Trimarchi, H., Zhang, H., Wang, W., Kocyigit, I., Hao, C., Tesař, V., Turgutalp, K., Yang, L., Xing, G., Duro Garcia, V., Han, S. H., Lu, W., Pisani, A., …, & APPLAUSE-IgAN Study Group (2026). Iptacopan in IgA Nephropathy — Final 24-Month Data. New England Journal of Medicine, 395(5), 465-477. https://doi.org/10.1056/nejmoa2600743

Vancouver

Barratt J, Eren N, Kashihara N, Maes B, Rizk DV, Rovin B, et al. Iptacopan in IgA Nephropathy — Final 24-Month Data. New England Journal of Medicine. 2026;395(5):465-477. doi:10.1056/nejmoa2600743

BibTeX
@article{Barratt2026,
  author = {Barratt, Jonathan and Eren, Necmi and Kashihara, Naoki and Maes, Bart and Rizk, Dana V and Rovin, Brad and Trimarchi, Hernán and Zhang, Hong and Wang, Weiming and Kocyigit, Ismail and Hao, Chuanming and Tesař, Vladimir and Turgutalp, Kenan and Yang, Li and Xing, Guangqun and Duro Garcia, Valter and Han, Seung Hyeok and Lu, Wanhong and Pisani, Antonio and Weinmann-Menke, Julia and Eitner, Frank and Guerard, Nicolas and Butylin, Dmytro and Monaco, Luca and Scosyrev, Emil and Magirr, Annabel and Renfurm, Ronny and Hach, Thomas and Perkovic, Vlado and APPLAUSE-IgAN Study Group, APPLAUSE-IgAN Study Group},
  title = {Iptacopan in IgA Nephropathy — Final 24-Month Data},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {5},
  pages = {465--477},
  doi = {10.1056/nejmoa2600743}
}
Kostenlos starten →